Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 213-221

  Zhang, Zhenbo ^a   Dong, Lingling ^b,c   Sui, Long ^d   Yang, Yixia ^a   Liu, Xuelian ^a   Yu, Yinhua ^d   Zhu, Yaping ^a   Feng, Youji ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Endometrial cancer; GloI apoptosis; Metformin; Progestin resistance

Indexed keywords

HYDROXYACYLGLUTATHIONE HYDROLASE; MAMMALIAN TARGET OF RAPAMYCIN; MEDROXYPROGESTERONE ACETATE; METFORMIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; ISCHIKAWA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, ENDOMETRIOID; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; LACTOYLGLUTATHIONE LYASE; METFORMIN; PROGESTINS; TUMOR CELLS, CULTURED;

EID: 79956141892     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318207dac7     Document Type: Article

References (25)

1. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology. 2007;39:72-87.
2. Pagel J, Bock JE. Endometrial cancer. A review. Dan Med Bull. 1984;31:333-345.
3. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335: 640-649. (Pubitemid 26277956)
4. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295-308. (Pubitemid 30207514)
5. Lucenteforte E, Bosetti C, Talamini R, et al. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer. 2007;97:995-998. (Pubitemid 47519295)
6. Saltzman BS, Doherty JA, Hill DA, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol. 2008;167: 607-614. (Pubitemid 351323306)
7. Berstein LM, Kvatchevskaya JO, Poroshina TE, et al. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004;130:687-693. (Pubitemid 39506383)
8. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106:2376-2381. (Pubitemid 43787661)
9. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol. 2004;117:132-137. (Pubitemid 39487319)
10. Minaguchi T, Nakagawa S, Takazawa Y, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage IA, G1 adenocarcinoma of the endometrium. Cancer Lett. 2007;248:112-122.
11. Hahn HS, Yoon SG, Hong JS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19:1068-1073.
12. Zhao S, Chen X, Lu X, et al. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol. 2007;105:45Y54. (Pubitemid 46441469)
13. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297-3302.
14. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330:1304-1305. (Pubitemid 40813563)
15. Session DR, Kalli KR, Tummon IS, et al. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol. 2003;17:405-407. (Pubitemid 37338871)
16. Sakamoto H, Mashima T, Kizaki A, et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood. 2000;95:3214-3218. (Pubitemid 30321176)
17. Sakamoto H, Mashima T, Sato S, et al. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res. 2001;7:2513-2518. (Pubitemid 32751657)
18. Davies GF, Roesler WJ, Juurlink BH, et al. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma. 2005;46:1199-1206. (Pubitemid 41087027)
19. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511.
20. Zhao SJ, Chen XJ, Feng YJ. Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell [in Chinese]. Fen Zi Xi Bao Sheng Wu Xue Bao. 2007;40:103-112.
21. Zivanovic O, Carter J, Kauff ND, et al. A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol. 2009;115:504-509.
22. Hoekstra AV, Kim JJ, Keh P, et al. Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med. 2008;53:869-873.
23. Smid-Koopman E, Kuhne LC, Hanekamp EE, et al. Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA- and/or PRB-expressing endometrial cancer cell lines. J Soc Gynecol Investig. 2005;12:285-292. (Pubitemid 40615100)
24. Takeuchi T, Chimura H, Hamada M, et al. A glyoxalase I inhibitor of a new structural type produced by Streptomyces. J Antibiot (Tokyo). 1975;28:737-742.
25. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol. 2008;112:465-467.